Bad blood: secrets and lies in a Silicon Valley Startup
(Book)
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Carreyrou, J. (2020). Bad blood: secrets and lies in a Silicon Valley Startup. First Vintage Books Edition. New York, Vintage Books, a division of Penguin Random House LLC.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John. 2020. Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Vintage Books, a division of Penguin Random House LLC.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John, Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Vintage Books, a division of Penguin Random House LLC, 2020.
MLA Citation (style guide)Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup. First Vintage Books Edition. New York, Vintage Books, a division of Penguin Random House LLC, 2020.
Notes
Record Information
| Last Sierra Extract Time | Mar 03, 2024 07:54:13 AM |
|---|---|
| Last File Modification Time | Mar 03, 2024 07:54:29 AM |
| Last Grouped Work Modification Time | Apr 27, 2024 04:11:17 AM |
MARC Record
| LEADER | 06034cam a2200625 i 4500 | ||
|---|---|---|---|
| 001 | 1059317847 | ||
| 003 | OCoLC | ||
| 005 | 20200624065709.7 | ||
| 008 | 200214t20202020nyuaf b 001 0 eng | ||
| 010 | |a 2019300476 | ||
| 020 | |a 9780525431992|q (pbk) | ||
| 020 | |a 0525431993 | ||
| 035 | |a (OCoLC)1059317847 | ||
| 040 | |a DLC|b eng|e rda|c DLC|d BDX|d GP5|d LTSCA|d OCLCF|d HKHPL|d MBT|d GL4|d YDX|d OCLCO | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 049 | |a CDFA | ||
| 050 | 0 | 0 | |a HD9995.H423|b U627 2020 |
| 082 | 0 | 0 | |a 338.7/681761|2 23 |
| 100 | 1 | |a Carreyrou, John,|0 https://id.loc.gov/authorities/names/n2018014999|e author. | |
| 245 | 1 | 0 | |a Bad blood :|b secrets and lies in a Silicon Valley Startup /|c John Carreyrou. |
| 250 | |a First Vintage Books Edition. | ||
| 264 | 1 | |a New York :|b Vintage Books, a division of Penguin Random House LLC,|c 2020. | |
| 300 | |a x, 341 pages, 8 unnumbered pages of plates :|b illustrations ;|c 21 cm | ||
| 336 | |a text|b txt|2 rdacontent | ||
| 337 | |a unmediated|b n|2 rdamedia | ||
| 338 | |a volume|b nc|2 rdacarrier | ||
| 504 | |a Includes bibliographical references (pages 307-326) and index. | ||
| 505 | 0 | 0 | |g Prologue --|t A purposeful life --|t Gluebot --|t Apple envy --|t Goodbye East Paly --|t Childhood neighbor --|t Sunny --|t Dr. J --|t MiniLab --|t Wellness play --|t "Who is LTC Shoemaker?" --|t Lighting a Fuisz --|t Ian Gibbons --|t Chiat\Day --|t Going live --|t Unicorn --|t Grandson --|t Fame --|t Hippocratic Oath --|t Tip --|t Ambush --|t Trade secrets --|t La mattanza --|t Damage control --|t Empress has no clothes. |
| 520 | |a "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--|c Provided by publisher. | ||
| 520 | |a "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--|c Provided by publisher. | ||
| 590 | |a GOBI Library Solutions from EBSCO|b Gobi Main Collection | ||
| 610 | 2 | 0 | |a Theranos (Firm)|0 https://id.loc.gov/authorities/names/n2018015605|x History.|0 https://id.loc.gov/authorities/subjects/sh99005024 |
| 610 | 2 | 7 | |a Theranos (Firm)|2 fast|0 (OCoLC)fst02009828 |
| 650 | 0 | |a Hematologic equipment industry|0 https://id.loc.gov/authorities/subjects/sh85060127|z United States.|0 https://id.loc.gov/authorities/names/n78095330-781 | |
| 650 | 0 | |a Fraud|z United States.|0 https://id.loc.gov/authorities/subjects/sh2008120324 | |
| 650 | 7 | |a Hematologic equipment industry.|2 fast|0 (OCoLC)fst00954898 | |
| 650 | 7 | |a Securities fraud.|2 fast|0 (OCoLC)fst01110802 | |
| 651 | 7 | |a United States.|2 fast|0 (OCoLC)fst01204155 | |
| 655 | 7 | |a History.|2 fast|0 (OCoLC)fst01411628 | |
| 655 | 7 | |a Trials, litigation, etc.|2 fast|0 (OCoLC)fst01423712 | |
| 907 | |a .b61064634 | ||
| 935 | |a .o28361891 | ||
| 948 | |a MARCIVE Overnight, in 2023.02 | ||
| 948 | |a MARCIVE Overnight, 06/2020 | ||
| 948 | |a MARCIVE Overnight, 05/2020 | ||
| 989 | |1 .i130024296|b 1240058432882|d ssbnf|g -|m |h 8|x 1|t 0|i 4|j 7|k 200417|n 02-26-2023 16:57|o -|a 338.7|r CAR | ||
| 989 | |1 .i130708070|b 1070004256186|d flgmn|g -|m |h 1|x 0|t 0|i 0|j 18|k 200626|n 11-01-2021 17:55|o -|a HD9995.H423|r U627 2020 | ||
| 994 | |a 92|b CDF | ||
| 995 | |a Loaded with m2btab.ltiac in 2023.02 | ||
| 995 | |a Loaded with m2btab.ltiac in 2020.07 | ||
| 995 | |a Loaded with m2btab.wcp in 2020.07 | ||
| 995 | |a Loaded with m2btab.ltiac in 2020.05 | ||
| 995 | |a Loaded with m2btab.b in 2020.04 | ||
| 998 | |e -|f eng|a fl|a ss|a ssb | ||
